SOUTH SAN FRANCISCO, CA--(Marketwire - November 29, 2011) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold’s Chief Executive Officer, is scheduled to present at the 2011 Oppenheimer 22nd Annual Healthcare Conference in New York City on Tuesday, December 13, 2011 at 9:55AM EST.
A live webcast of the presentation will be available under the Webcast section of the Company’s Website at www.thresholdpharm.com
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
Contact:
Joel A. Fernandes
Threshold Pharmaceuticals, Inc.
650.474.8273
IR@thresholdpharm.com
